Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • Ernexa Therapeutics' Cash from Operations rose 7931.58% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year increase of 4428.39%. This contributed to the annual value of -$15.8 million for FY2024, which is 2240.3% up from last year.
  • According to the latest figures from Q3 2025, Ernexa Therapeutics' Cash from Operations is -$1.3 million, which was up 7931.58% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Cash from Operations registered a high of -$1.3 million during Q3 2025, and its lowest value of -$6.3 million during Q3 2024.
  • Its 5-year average for Cash from Operations is -$4.2 million, with a median of -$3.9 million in 2022.
  • Per our database at Business Quant, Ernexa Therapeutics' Cash from Operations crashed by 8311.96% in 2021 and then soared by 7931.58% in 2025.
  • Ernexa Therapeutics' Cash from Operations (Quarter) stood at -$3.4 million in 2021, then crashed by 58.45% to -$5.4 million in 2022, then increased by 14.24% to -$4.7 million in 2023, then increased by 23.94% to -$3.5 million in 2024, then surged by 63.33% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$2.5 million for Q2 2025, and -$2.1 million during Q1 2025.